Impact of alternative payment models on specialist care for patients with new-onset end-stage renal disease

替代支付模式对新发终末期肾病患者专科护理的影响

基本信息

  • 批准号:
    10244998
  • 负责人:
  • 金额:
    $ 3.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary Background: End-stage renal disease (ESRD), which affected >746,000 Americans in 2017, is the final stage of chronic kidney disease, leading to death unless renal replacement therapy is initiated. Of the treatment options available (in-center hemodialysis, home dialysis, kidney transplantation), transplantation is the preferred modality, offering the best survival time, quality of life outcomes, and lowest average cost. Home dialysis modalities are also less costly than in-center dialysis and associated with improved patient satisfaction. Despite these advantages, <15% of incident ESRD patients received home dialysis or a living donor kidney transplant in 2016, and only 14% of patients joined a transplant waiting list or received a transplant within one year of initiating treatment. The Advancing American Kidney Health initiative (July 2019) proposes to enroll 50% of ESRD care providers in a shared-risk alternative payment model (APM) that would tie providers' payment to cost savings on health service use, with the goal of increasing use of cost-effective treatments (home dialysis and transplantation). Currently, no evidence exists about nephrologist participation in APMs, or their impact on treatment outcomes in specialty care. This study will examine nephrologist participation in two shared-risk APMs (accountable care organizations [ACOs] and ESRD seamless care organizations [ESCOs]), to characterize the population of APM-affiliated nephrologists and estimate the impact of nephrologist APM affiliation on treatment use and clinical outcomes for patients with new-onset ESRD. Data: This project will link 11 years (2006-2017) of United States Renal Disease System data—rich clinical and administrative data for >1,250,000 incident ESRD patients and >7,500 dialysis facilities—to provider-level data on ACO (Medicare Shared Savings Program Provider-level files) and ESCO participation (provider-level public data). Several additional public data sets (e.g., US Census Bureau, CMS Hospital Compare) will supplement the provider- level dataset with facility and community characteristics. Analysis: Aim 1 will test associations between APM affiliation and nephrologists' key geographic, sociodemographic, and facility characteristics using logistic regression models. Aim 2 will estimate the impact of nephrologist APM participation on treatment use and ESRD patient health outcomes using rigorous quasi-experimental methods (difference-in-difference regression), comparing nephrologists' treatment use and patients' outcomes before and after APM affiliation, relative to contemporary changes in these outcomes among never-affiliated nephrologists during an 11-year period of widespread APM adoption. Implications: APM participation will be mandatory for half of ESRD care providers in 2020. This research will provide foundational information about nephrologists that have been affiliated with APMs to date and about the impact of APM affiliation on treatment use and health outcomes for patients with new-onset ESRD. Importantly, this study's findings will inform broader policy and health systems deliberations about the design and implementation of APMs in specialty care settings.
项目摘要 背景:终末期肾病(ESRD)是2017年影响超过746,000名美国人的最后阶段, 慢性肾脏疾病,导致死亡,除非肾脏替代治疗开始。治疗 可用的选择(中心血液透析,家庭透析,肾移植),移植是 首选的方式,提供最佳的生存时间,生活质量的结果,和最低的平均成本。家 透析方式也比中心透析便宜,并且与提高的患者满意度相关。 尽管有这些优势,但<15%的ESRD患者接受了家庭透析或活体供肾 在2016年的移植中,只有14%的患者加入了移植等待名单或在一年内接受了移植。 开始治疗的年份。推进美国肾脏健康倡议(2019年7月)提议招募 50%的ESRD护理提供者采用风险分担替代支付模式(APM), 支付保健服务使用的费用节省,目的是增加使用具有成本效益的治疗 (home透析和移植)。目前,没有证据表明肾病学家参与了APM,或 它们对专科护理治疗结果的影响。这项研究将检查肾脏科医生参与两个 风险分担APM(责任护理组织[ACO]和ESRD无缝护理组织[ESCO]), 描述APM附属肾病学家人群的特征,并估计肾病学家APM的影响 与新发ESRD患者的治疗使用和临床结果的联系。数据:该项目将连接 11年(2006-2017)美国肾脏疾病系统数据丰富的临床和管理数据, > 1,250,000例ESRD患者和> 7,500家透析机构-ACO(医疗保险)提供者级数据 共享储蓄计划提供商级文件)和共享储蓄计划参与(提供商级公共数据)。几 附加的公共数据集(例如,美国人口普查局,CMS医院比较)将补充供应商- 具有设施和社区特征的水平数据集。分析:目标1将测试APM之间的关联 使用Logistic回归分析的关系和肾病学家的关键地理、社会人口和设施特征 回归模型目标2将评估肾病学家APM参与对治疗使用的影响, 使用严格的准实验方法(差异中的差异)评估ESRD患者的健康结局 回归),比较APM加入前后肾病学家的治疗使用和患者的结局, 相对于11年期间从未隶属的肾病学家中这些结果的当代变化, 广泛采用APM的时期。影响:对于一半的ESRD护理,APM参与将是强制性的 供应商在2020年。这项研究将提供有关肾病学家的基础信息, 以及加入APM对治疗使用和健康结果的影响, 新发ESRD患者。重要的是,这项研究的发现将为更广泛的政策和卫生系统提供信息。 在专科护理环境中设计和实施APM的审议。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kelsey Drewry其他文献

Kelsey Drewry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了